Open access · CC-BY
via OpenAlex
Recent Advances in Age-Related Macular Degeneration Therapies
Marie Fabre, Lou Mateo, Diana Lamaa, Stéphanie Baillif, Gilles Pagès, Luc Demange, Cyril Ronco, Rachid Benhida
Molecules · 2022 · ▲ 95 citations
Abstract
Age-related macular degeneration (AMD) was described for the first time in the 1840s and is currently the leading cause of blindness for patients over 65 years in Western Countries. This disease impacts the eye's posterior segment and damages the macula, a retina section with high levels of photoreceptor cells and responsible for the central vision. Advanced AMD stages are divided into the atrophic (dry) form and the exudative (wet) form. Atrophic AMD consists in the progressive atrophy of the retinal pigment epithelium (RPE) and the outer retinal layers, while the exudative form results in the anarchic invasion by choroidal neo-vessels of RPE and the retina. This invasion is responsible for fluid accumulation in the intra/sub-retinal spaces and for a progressive dysfunction of the photoreceptor cells. To date, the few existing anti-AMD therapies may only delay or suspend its progression, without providing cure to patients. However, in the last decade, an outstanding number of research programs targeting its different aspects have been initiated by academics and industrials. This review aims to bring together the most recent advances and insights into the mechanisms underlying AMD pathogenicity and disease evolution, and to highlight the current hypotheses towards the development of new treatments, i.e., symptomatic vs. curative. The therapeutic options and drugs proposed to tackle these mechanisms are analyzed and critically compared. A particular emphasis has been given to the therapeutic agents currently tested in clinical trials, whose results have been carefully collected and discussed whenever possible.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3390/molecules27165089
- Canonical
- link ↗
- Fetched
- 2026-11-05 MST
Cite this
APA
Fabre, M., Mateo, L., Lamaa, D., Baillif, S., Pagès, G., Demange, L., Ronco, C., & Benhida, R. (2022). Recent Advances in Age-Related Macular Degeneration Therapies. <em>Molecules</em>. https://doi.org/10.3390/molecules27165089
Vancouver
Fabre M, Mateo L, Lamaa D, Baillif S, Pagès G, Demange L, et al. Recent Advances in Age-Related Macular Degeneration Therapies. Molecules. 2022. doi:10.3390/molecules27165089.
BibTeX
@article{marie2022Recent,
title = {Recent Advances in Age-Related Macular Degeneration Therapies},
author = {Marie Fabre and Lou Mateo and Diana Lamaa and Stéphanie Baillif and Gilles Pagès and Luc Demange and Cyril Ronco and Rachid Benhida},
journal = {Molecules},
year = {2022},
doi = {10.3390/molecules27165089},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Current Opinion in Ophthalmology 2002
Citation only
Risk factors for age-related macular degeneration: an update
Annals of Medicine 2006
Open access · OA
Age‐related macular degeneration—emerging pathogenetic and therapeutic concepts
Hospices Civils de Lyon 2017
Open access · US-GOV
Comparison of Cytokine Profiles in Aqueous Humor of Patients With Age Related Macular Degeneration (AMD)
Medical University of Vienna 2011
Open access · US-GOV
Comparison of Intravitreal Dexamethasone With Intravitreal Ranibizumab Versus Intravitreal Ranibizumab Monotherapy in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular Degeneration A Prospective, Randomized, Clinical Study
Clinical Interventions in Aging 2008
Open access · CC-BY
Age-related macular degeneration and the aging eye
Journal of Clinical Medicine 2021
Open access · CC-BY